Arcturus Therapeutics Holdings Inc.
ARCTNASDAQHealthcare● Active
$7.11
$-0.20(-2.67%)
Market Cap$201945905
P/E Ratio—
52W High$24.17
52W Low$5.85
Arcturus Therapeutics Holdings Inc. (ARCT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ARCT · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.95
Est. -$1.03 · +7.9%
Revenue
$0.00B
Est. $0.01B · -67.3%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 1-Quarter EPS Beat Streak
ARCT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 10, 2026 | -$1.00 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$1.03 | -$0.95 | +7.9% | $0.00B | $0.01B | -67.3% |
| ▼ Q1 FY2026 | Mar 3, 2026 | -$0.92 | -$1.03 | -12.0% | $0.01B | $0.02B | -54.8% |
| ▲ Q4 FY2025 | Nov 10, 2025 | -$0.80 | -$0.49 | +38.7% | $0.02B | $0.02B | +7.0% |
| ▲ Q3 FY2025 | Aug 11, 2025 | -$1.11 | -$0.34 | +69.4% | $0.02B | $0.02B | +33.6% |
| ▲ Q2 FY2025 | May 12, 2025 | -$1.58 | -$0.52 | +67.1% | $0.03B | $0.02B | +25.8% |
| ▼ Q1 FY2025 | Mar 6, 2025 | -$0.33 | -$1.11 | -236.4% | $0.02B | $0.04B | -53.0% |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.70 | -$0.26 | +62.9% | $0.04B | $0.05B | -15.5% |
Q3 FY2026
Aug 10, 2026
EPS Actual
—
EPS Est.
-$1.00
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.95
EPS Est.
-$1.03
EPS Surpr.
+7.9%
Revenue
$0.00B
Q1 FY2026
Mar 3, 2026Miss
EPS Actual
-$1.03
EPS Est.
-$0.92
EPS Surpr.
-12.0%
Revenue
$0.01B
Q4 FY2025
Nov 10, 2025Beat
EPS Actual
-$0.49
EPS Est.
-$0.80
EPS Surpr.
+38.7%
Revenue
$0.02B
Q3 FY2025
Aug 11, 2025Beat
EPS Actual
-$0.34
EPS Est.
-$1.11
EPS Surpr.
+69.4%
Revenue
$0.02B
Q2 FY2025
May 12, 2025Beat
EPS Actual
-$0.52
EPS Est.
-$1.58
EPS Surpr.
+67.1%
Revenue
$0.03B
Q1 FY2025
Mar 6, 2025Miss
EPS Actual
-$1.11
EPS Est.
-$0.33
EPS Surpr.
-236.4%
Revenue
$0.02B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.26
EPS Est.
-$0.70
EPS Surpr.
+62.9%
Revenue
$0.04B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-2.86 | $-0.56 | $-0.07 | 2 |
| Q3 FY2027 | $-4.11 | $-0.81 | $-0.10 | 2 |
| Q2 FY2027 | $-5.06 | $-0.99 | $-0.12 | 2 |
| Q1 FY2027 | $-4.81 | $-0.94 | $-0.12 | 3 |
| Q4 FY2026 | $-5.61 | $-1.10 | $-0.14 | 3 |
| Q3 FY2026 | $-1.10 | $-1.00 | $-0.92 | 7 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.1B | 7 |
| Q3 FY2027 | $0.0B | $0.0B | $0.1B | 4 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 6 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 4 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 7 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 8 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +7.9% | $9.13 | $8.90 | -2.52% |
| ▼ Q1 FY2026 | Mar 3, 2026 | -12.0% | $8.35 | $7.91 | -5.27% |
| ▲ Q4 FY2025 | Nov 10, 2025 | +38.7% | $8.72 | $8.78 | +0.69% |
| ▲ Q3 FY2025 | Aug 11, 2025 | +69.4% | $11.91 | $11.39 | -4.37% |
| ▲ Q2 FY2025 | May 12, 2025 | +67.1% | $10.98 | $11.59 | +5.56% |
| ▼ Q1 FY2025 | Mar 6, 2025 | -236.4% | $16.05 | $15.97 | -0.50% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +62.9% | $18.33 | $18.74 | +2.24% |
| ▲ Q3 FY2024 | Aug 5, 2024 | +65.4% | $20.55 | $19.79 | -3.70% |
Q2 FY2026-2.52%
Report Date
May 7, 2026
EPS Beat/Miss
+7.9%
Price Before
$9.13
Price After
$8.90
Q1 FY2026-5.27%
Report Date
Mar 3, 2026
EPS Beat/Miss
-12.0%
Price Before
$8.35
Price After
$7.91
Q4 FY2025+0.69%
Report Date
Nov 10, 2025
EPS Beat/Miss
+38.7%
Price Before
$8.72
Price After
$8.78
Q3 FY2025-4.37%
Report Date
Aug 11, 2025
EPS Beat/Miss
+69.4%
Price Before
$11.91
Price After
$11.39
Q2 FY2025+5.56%
Report Date
May 12, 2025
EPS Beat/Miss
+67.1%
Price Before
$10.98
Price After
$11.59
Q1 FY2025-0.50%
Report Date
Mar 6, 2025
EPS Beat/Miss
-236.4%
Price Before
$16.05
Price After
$15.97
Q4 FY2024+2.24%
Report Date
Nov 7, 2024
EPS Beat/Miss
+62.9%
Price Before
$18.33
Price After
$18.74
Q3 FY2024-3.70%
Report Date
Aug 5, 2024
EPS Beat/Miss
+65.4%
Price Before
$20.55
Price After
$19.79
Avg Beat Reaction-0.35%
Avg Miss Reaction-2.88%
Beat Rate6 / 8 quarters
Largest Move+5.56% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ARCT ends December
Arcturus Therapeutics Holdings Inc. (ARCT) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.95 — beating the analyst consensus of $-1.03 by +7.9%. The next ARCT earnings date is expected around September 1, 2026.
Each quarter, investors track ARCT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ARCT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ARCT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ARCT earnings · 5 questionsArcturus Therapeutics Holdings Inc.'s next earnings report is expected around September 1, 2026. ARCT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ARCT historically reports after market close (AMC).
ARCT earnings datewhen is ARCT earningsARCT next earnings datewhen does ARCT report earningsARCT earnings calendar
▸ Source: FMP · Arcturus Therapeutics Holdings Inc. SEC filings · US GAAP · Arcturus Therapeutics Holdings Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026